Fig. 1: Efhd2 deficiency exacerbates DSS-induced colitis.
a Representative images of immunostaining for EFHD2 on intestinal biopsy samples from ulcerative colitis (UC) patients at the active or the remission stage, healthy controls and controls stained only with the secondary antibody. Scale bar, 300 μm. Solid arrowheads show intestinal epithelium and hollow arrowheads show the lamina propria. b Representative images of immunostaining for Efhd2 on distal colon tissues from C57BL/6J mice treated with 3% dextran sodium sulfate (DSS) for 6 days and sacrificed at the indicated time with secondary antibody controls. Scale bar, 400 μm. Solid arrowheads show intestinal epithelium and hollow arrowheads show the lamina propria. c Histologic scores of EFHD2 (a) and Efhd2 (b) staining were using a 3-point quantification scale. UC patients at the active or the remission stage (n = 10 each group), healthy controls (n = 9) in a. n = 6 mice each group in b. Relative percentage of body weight change (d), disease activity index (DAI) (e), and representative images and lengths of the colon (f) of WT and Efhd2-/- mice after 3% DSS administration for 6 days and sacrificed on day 7. Representative images of hematoxylin and eosin (H&E) staining of distal colon (g) and histologic scores (h) of WT and Efhd2-/- mice subjected to DSS-induced colitis on day 0 and day 7. Left scale bar, 100 μm; right scale bar, 200 μm; arrows show intestinal goblet cells in g. n = 6 mice each group (d–f, h). Data are representative of three independent experiments; error bars show means ± s.d. P values were determined by unpaired two-tailed t-test. For body weight curves, two-way ANOVA analysis with Sidak’s multiple comparisons test. Source data are provided as a Source Data file.
